A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Summary

A single-center, open-label, off-label use investigator-initiated clinical study to explore the clinical activity and safety of daratumumab in adult ITP patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including rituximab and/or TPO-RA.

Timeline

Start

2022-12-10

Primary completion

2025-01-31

Completion

2025-12-31

Publications

• Chen Y, Hua Z, Xu Y, Chen J, Wen Q, Sun T, Li H, Liu X, Fu R, Ju M, Xue F, Liu W, Dong H, Gu W, Dai X, Wang W, Chi Y, Pei X, Yang R, Zhang L. Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial. EClinicalMedicine. 2026 Mar 26;94:103849. doi: 10.1016/j.eclinm.2026.103849. eCollection 2026 Apr.

Drugs

Indications